ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / GPCR
PAHC (56) INVA (65) RARE (23) OCUL (24) ⌘ Pro Terminal →

Structure Therapeutics Inc. (GPCR) — RQD Stock Rating Cockpit

$20.47 -6.40% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $20.20

Structure Therapeutics Inc. (GPCR) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $1.56B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GPCR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GPCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Structure Therapeutics Inc. (NASDAQ: GPCR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $20.47 (-6.40% 1D, market cap $1.56B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, GPCR ranks #880 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GPCR compare to PAHC and INVA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GPCR carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -19.5%. By comparison, PAHC (Phibro Animal Health Corporation (Class A)) holds a D+ grade (56/100 RQD, P/E 32.7x, ROIC 9.9%, cap $1.58B) and INVA (Innoviva Inc.) posts a C grade (65/100 RQD, P/E N/A, ROIC 14.7%, cap $1.53B). Among the 5-stock peer group, PAHC leads on earnings multiple (32.7x) while INVA leads on capital efficiency (14.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GPCR?
▼

Per GPCR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001888886), Structure Therapeutics Inc. generated $494.4M in revenue (+11.6% YoY), -$141.2M in net income, and -$225.8M in free cash flow against $1.58B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $20.20 (-1.34%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510027
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (4)Whales (3)SEC (10)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-14% Base Target
$100 Bull$18 Base$14 Bear
📬 FREE GPCR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GPCR)Realized 20D OHLCV Swing Band: ±11.4%
Deterministic 5-Pillar Attribution (27/100 Composite)
🔍 WHY GPCR SCORES 27/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (37% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (26% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 26.9 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
35
Grade E$22.31+2.6% Next Q
Q2 (-2Q)
32
Grade E$22.88-5.8% Next Q
Q3 (-1Q)
30
Grade E$21.55-5% Next Q
Current
27
Grade E$20.47-10.3% Hist 90D α
Trajectory: E (35) → E (27)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a GPCR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While GPCR currently carries a cautious 27/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($32.35) and Max Pain ($21.49) forces dealer call-delta covering toward $99.65.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GPCR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GPCR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 27%NO 73%Trade / Inspect Odds →
RSI-14 MOMENTUMOVERSOLD (<32)
26.930 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
1 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $21$20.47H: $95
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 6 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 17 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on GPCR

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (20)

-19.5% ROIC with 42.0% gross margin and -14.43% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 1/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (22)

6/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like GPCR
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GPCR)

  • ✓Walkthrough of GPCR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
GPCR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -52.44%🛡️ HOLDING TREND SUPPORT
2026-11-03O $21.94H $21.94L $20.47C $20.47VOL 697.0K
RES: $52.95SUP: $19.01SMA50: $32.35SMA200: $48.41
$59.63$49.02$38.40$27.79$17.18RES $52.95SUP $19.01$20.472026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GPCR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GPCR Butterfly Map → + Track GPCR →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +11.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on GPCR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GPCR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GPCR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GPCR)

Health Care Rank #880 of 1015 ⚔️ PAHC vs GPCR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GPCR vs. PAHC, INVA, RARE, OCUL)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Structure Therapeutics Inc. (GPCR) ranks #880 by composite RQD confidence (27/100, grade E) and #296 by equity capitalization ($1.56B). Within this direct 5-issuer industry benchmark cohort, PAHC leads on earnings valuation at 32.7x trailing P/E, while INVA leads on capital efficiency and profitability with 14.7% ROIC and 74.8% gross margin. INVA currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with GPCR at 27/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
GPCR ACTIVE
Structure Therapeutics Inc.
E 27/100 — — -19.5% -6.40% $1.56B Benchmark Subject
PAHC
Phibro Animal Health Corporation (Class A)
D+ 56/100 32.7x 30.9% 9.9% -0.36% $1.58B /pahc-vs-gpcr →
INVA
Innoviva Inc.
C 65/100 — 74.8% 14.7% -0.94% $1.53B /inva-vs-gpcr →
RARE
Ultragenyx Pharmaceutical Inc.
E 23/100 — — -35.0% +1.24% $1.59B /rare-vs-gpcr →
OCUL
Ocular Therapeutix Inc.
E 24/100 — 87.3% -35.0% -3.44% $1.53B /ocul-vs-gpcr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001888886 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Structure Therapeutics Inc. (GPCR) reported GAAP revenue of $494.4M (+11.6% vs. FY2024 revenue of $443.0M , and +71.8% cumulative change since FY2023) , GAAP net income of -$141.2M, operating cash flow of -$222.2M, and free cash flow of -$225.8M (-91.5% YoY). On the balance sheet, GPCR closed FY2025 with $1.58B in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $494.4M -$141.2M -$222.2M -$225.8M $1.58B —
FY2024 (FY) 2024-12-31 $443.0M -$122.5M -$116.6M -$117.9M $903.3M —
FY2023 (FY) 2023-12-31 $287.8M -$89.6M -$79.5M -$79.5M — —

3. GPCR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GPCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Structure Therapeutics Inc. (NASDAQ: GPCR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $20.47 (-6.40% 1D, market cap $1.56B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, GPCR ranks #880 in composite RQD confidence.

How does GPCR compare to PAHC and INVA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GPCR carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -19.5%. By comparison, PAHC (Phibro Animal Health Corporation (Class A)) holds a D+ grade (56/100 RQD, P/E 32.7x, ROIC 9.9%, cap $1.58B) and INVA (Innoviva Inc.) posts a C grade (65/100 RQD, P/E N/A, ROIC 14.7%, cap $1.53B). Among the 5-stock peer group, PAHC leads on earnings multiple (32.7x) while INVA leads on capital efficiency (14.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GPCR?

Per GPCR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001888886), Structure Therapeutics Inc. generated $494.4M in revenue (+11.6% YoY), -$141.2M in net income, and -$225.8M in free cash flow against $1.58B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GPCR trading relative to its 50-day, 200-day, and 52-week technical levels?

GPCR last traded at $20.47 (-6.40% on volume of 788,407 shares), positioning the stock -36.72% below its 50-day simple moving average ($32.35) and -57.72% below its 200-day simple moving average ($48.41). Across its 52-week range of $20.50 to $94.90, GPCR sits at the 0.0% percentile with a 14-day RSI of 26.9 (OVERSOLD (<32)) and an implied next-earnings move of ±11.4% ($18.14 to $22.80).

Direct Sub-Reports: GPCR RQD Cockpit GPCR 12M Forecast GPCR Earnings & Move GPCR Dividends & DRIP GPCR Insiders & 13F GPCR Whale Options GPCR Profit Sankey GPCR News & Why
ROARABLE RATING BRIEF • RQD 27/100 (E) ✓ SEC XBRL & RQD VERIFIED

GPCR — Structure Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Structure Therapeutics Inc. (GPCR) earns a live Roarable RQD composite score of 27/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $20.47 (-6.40% 1D, market capitalization $1.56B).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -19.5%, gross margin of —, operating margin of —, and free cash flow yield of -14.43%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Structure Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Structure Therapeutics Inc. (GPCR) reported $494.4M in annual revenue (up from $443.0M in FY2024, +11.6% YoY) and -$141.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($287.8M revenue, -$89.6M net income) through FY2025, GPCR scaled operating cash flow to -$222.2M and free cash flow to -$225.8M, backed by $1.58B in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 27/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -14.43% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $20.50 – $94.90 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), GPCR carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can GPCR sustain or expand its — operating margin and -19.5% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $494.4M and free cash flow of -$225.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is GPCR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

GPCR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Structure Therapeutics Inc. (GPCR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GPCR Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GPCR Bull vs. Bear Conversation Board — What's Your Call at $20.47?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GPCR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on GPCR:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $26.46 (+21.0%)
📌 Pinned Debate

Cited news wire positioning that the stock may be a bargain given its asset base, paired with a $799.6M cash balance in FY 2025.

Cited news wire positioning that the stock may be a bargain given its asset base, paired with a $799.6M cash balance in FY 2025.. When you look under the hood at GPCR, Fundamental Cash Engine is 4/20 with 0.0% gross margins and -19.5% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $94.90. My 12M target is $26.46.

EarningsSniper 🐂 BULL

@MultipleCompression Shorting a 3/20 institutional whale-flow stock at $21.87 is dangerous when funds are rotating into Health Care.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $16.40 (-25.0%)
Spot @ $21.87

Negative ROIC of -19.5%, FCF of -$225.8M in FY 2025, and a Piotroski F-Score of 1 out of 9 indicate weak cash generation and forensic q

Careful chasing GPCR at $21.87. Negative ROIC of -19.5%, FCF of -$225.8M in FY 2025, and a Piotroski F-Score of 1 out of 9 indicate weak cash generation and forensic quality.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $16.40 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%